PIERIS PHARMACEUTICALS, INC. Contracts & Agreements

Form of Common Stock Certificate (Filed With SEC on December 16, 2024)

Separation Agreement, dated December 13, 2024, between Pieris Pharmaceuticals, Inc. and Stephen A. Yoder (Filed With SEC on December 16, 2024)

Separation Agreement, dated December 13, 2024, between Pieris Pharmaceuticals, Inc. and Thomas Bures (Filed With SEC on December 16, 2024)

Consulting Agreement, dated December 13, 2024, by and between Palvella Therapeutics, Inc. and Thomas Bures (Filed With SEC on December 16, 2024)

Registration Rights Agreement, dated as of December 13, 2024, by and among Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) and certain purchasers (Filed With SEC on December 16, 2024)

Contingent Value Rights Agreement, dated as of December 13, 2024, by and among, Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.), Shareholder Representative... (Filed With SEC on December 16, 2024)

Form of Stock Option Grant Notice and Stock Option Agreement (Filed With SEC on December 16, 2024)

Form of Notice of Grant of Restricted Stock Units Award (Filed With SEC on December 16, 2024)

Palvella Therapeutics, Inc.'s 2024 Equity Incentive Plan (Filed With SEC on December 12, 2024)

Separation Agreement by and between the Pieris Pharmaceuticals GmbH and Shane Olwill, Ph.D., dated as of July 23, 2024 (Filed With SEC on November 13, 2024)

Amended and Restated Articles of Incorporation, as amended on April 22, 2024 (Filed With SEC on August 14, 2024)

Form of Common Stock Certificate (Filed With SEC on August 14, 2024)

Palvella Therapeutics, Inc. 2019 Equity Incentive Plan (Filed With SEC on August 9, 2024)

Form of Incentive Stock Option Agreement under the Palvella Therapeutics, Inc. 2019 Equity Incentive Plan (Filed With SEC on August 9, 2024)

Form of Non-Qualified Stock Option Agreement under the Palvella Therapeutics, Inc. 2019 Equity Incentive Plan (Filed With SEC on August 9, 2024)

Amendment No. 1 to Palvella Therapeutics, Inc. 2019 Equity Incentive Plan (Filed With SEC on August 9, 2024)

Form of Indemnification Agreement by and between Palvella Therapeutics, Inc. and certain of its directors (Filed With SEC on August 9, 2024)

Form of Convertible Promissory Note (Filed With SEC on August 9, 2024)

Form of 2024 Convertible Note Purchase Agreement (Filed With SEC on August 9, 2024)

Office Building Lease, dated May 18, 2018, by and between The Strafford Office Buildings and Palvella Therapeutics, Inc (Filed With SEC on August 9, 2024)

First Amendment to Office Building Lease, dated September 30, 2020, by and between The Strafford Office Buildings and Palvella Therapeutics, Inc (Filed With SEC on August 9, 2024)

Development Funding and Royalties Agreement, dated December 13, 2018, by and between Ligand Pharmaceuticals, Inc. and Palvella Therapeutics, Inc (Filed With SEC on August 9, 2024)

First Amendment to Development Funding and Royalties Agreement, dated May 22, 2020, by and between Ligand Pharmaceuticals, Inc. and Palvella Therapeutics, Inc (Filed With SEC on August 9, 2024)

Second Amendment to Development Funding and Royalties Agreement, dated November 28, 2023, by and between Ligand Pharmaceuticals, Inc. and Palvella Therapeutics, Inc (Filed With SEC on August 9, 2024)

Employment Agreement, dated May 20, 2020, by and between Wesley Kaupinen and Palvella Therapeutics, Inc (Filed With SEC on August 9, 2024)

Offer Letter, dated August 31, 2018, by and between Kathleen A. McGowan and Palvella Therapeutics, Inc (Filed With SEC on August 9, 2024)

Severance Agreement, dated May 22, 2020, by and between Kathleen A. McGowan and Palvella Therapeutics, Inc (Filed With SEC on August 9, 2024)

Severance Agreement, dated May 22, 2020, by and between Kathleen Goin and Palvella Therapeutics, Inc (Filed With SEC on August 9, 2024)

Offer Letter, dated July 27, 2020, by and between Jeffrey Martini and Palvella Therapeutics, Inc (Filed With SEC on August 9, 2024)

Offer Letter, dated August 19, 2019, by and between Kathleen Goin and Palvella Therapeutics, Inc (Filed With SEC on August 9, 2024)

Subscription and Investment Representation Agreement, dated August 7, 2024, by and between Pieris Pharmaceuticals, Inc. and James Geraghty (Filed With SEC on August 8, 2024)

Agreement and Plan of Merger, dated as of July 23, 2024, by and among Pieris Pharmaceuticals, Inc., Polo Merger Sub, Inc. and Palvella Therapeutics, Inc (Filed With SEC on July 24, 2024)

Form of Pre-Funded Warrant (Filed With SEC on July 24, 2024)

Form of Contingent Value Rights Agreement (Filed With SEC on July 24, 2024)

Form of Palvella Support Agreement (Filed With SEC on July 24, 2024)

Form of Pieris Support Agreement (Filed With SEC on July 24, 2024)

Form of Lock-Up Agreement (Filed With SEC on July 24, 2024)

Securities Purchase Agreement, dated as of July 23, 2024, by and among Pieris Pharmaceuticals, Inc. and certain purchasers (Filed With SEC on July 24, 2024)

Form of Registration Rights Agreement (Filed With SEC on July 24, 2024)

License and Collaboration Agreement by and among the Registrant, Pieris GmbH and Seagen, Inc., dated February 8, 2018 (Filed With SEC on May 15, 2024)

Non-Exclusive Anticalin Platform Technology License Agreement by and among the Registrant, Pieris Pharmaceuticals GmbH and Seagen, Inc., dated February 8, 2018 (Filed With SEC on May 15, 2024)

Amendment No. 3 to Lease Agreement by and between Pieris GmbH and Hallbergmoos Grundvermgen GmbH, dated May 19, 2020 (English translation) (Filed With SEC on March 29, 2024)

Amendment No. 4 to Lease Agreement by and between Pieris GmbH and Hallbergmoos Grundvermgen GmbH, dated December 15, 2023 (English translation) (Filed With SEC on March 29, 2024)

Amendment No. 1, dated December 11, 2023, to Consulting Agreement by and between the Registrant and Ahmed Mousa (Filed With SEC on March 29, 2024)

Employment Agreement by and between Pieris GmbH and Shane Olwill, Ph.D. dated May 9, 2011 (Filed With SEC on March 29, 2024)

Amendments to the Employment Agreement by and between Pieris GmbH and Shane Olwill, Ph.D., dated between 2012-2021 (Filed With SEC on March 29, 2024)

Retention Letter by and between Pieris GmbH and Shane Olwill, Ph.D., dated February 22, 2024 (Filed With SEC on March 29, 2024)

Separation Agreement by and between the Registrant and Hitto Kaufmann, Ph.D., dated as of July 26, 2023 (Filed With SEC on November 14, 2023)

Consulting Agreement by and between the Registrant and Ahmed Mousa, dated as of September 11, 2023 (Filed With SEC on November 14, 2023)

Amendment No. 1, dated September 12, 2023, to the Amended and Restated License and Collaboration Agreementby and between the Registrant and Seagen Inc (Filed With SEC on November 14, 2023)

Pieris Pharmaceutical, Inc. 2023 Employee Stock Purchase Plan (Filed With SEC on August 10, 2023)

Pieris Pharmaceutical, Inc. 2020 Employee, Director and Consultant Equity Incentive Plan, as Amended (Filed With SEC on June 26, 2023)

Pieris Pharmaceutical, Inc. 2023 Employee Stock Purchase Plan (Filed With SEC on June 26, 2023)

Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 31, 2023)

Separation Agreement by and between Pieris Pharmaceuticals, Inc. and Tim Demuth, M.D., dated as of August 4, 2022 (Filed With SEC on November 4, 2022)

Amendment No. 5, dated August 1, 2022, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on November 4, 2022)

Amendment No. 1 to Sales Agreement, dated November 4, 2022, by and between Pieris Pharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on November 4, 2022)

Amendment No. 3, dated June 9, 2022, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on August 4, 2022)

Amendment No. 4, dated June 30, 2022, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on August 4, 2022)

Pieris Pharmaceuticals, Inc. 2020 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on June 27, 2022)

Employment Contract by and between Pieris Pharmaceuticals GmbH and Tim Demuth, M.D., Ph.D., dated as of August 1, 2021 (Filed With SEC on May 11, 2022)

Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 2, 2022)

Employment Agreement by and between Pieris Pharmaceuticals, Inc. and Ahmed Mousa, dated as of October 7, 2021 (Filed With SEC on November 2, 2021)

Employment Agreement by and between Pieris Pharmaceuticals, Inc. and Tom Bures, dated as of October 7, 2021 (Filed With SEC on November 2, 2021)

Exclusive Product License Agreement, dated April 24, 2021, by and among Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH and BP Asset XII, Inc (Filed With SEC on August 5, 2021)

Research Collaboration and License Agreement, dated May 19, 2021, by and among Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH and Genentech, Inc (Filed With SEC on August 5, 2021)

Pieris Pharmaceuticals, Inc. 2020 Employee, Director and Consultant Equity Incentive Plan, as Amended (Filed With SEC on June 29, 2021)

Exchange Agreement by and among Pieris Pharmaceuticals, Inc. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., and... (Filed With SEC on May 21, 2021)

Amended and Restated License and Collaboration Agreement, dated March 24, 2021, by and between Pieris Pharmaceuticals, Inc. and Seagen Inc (Filed With SEC on May 17, 2021)

Combination Study Agreement, dated March 24, 2021, by and among Pieris Pharmaceuticals, Inc. and Seagen Inc (Filed With SEC on May 17, 2021)

Subscription Agreement, dated March 24, 2021, by and between Pieris Pharmaceuticals, Inc. and Seagen Inc (Filed With SEC on May 17, 2021)

Amendment No. 2, dated March 29, 2021, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on May 17, 2021)

Amendment No. 1, dated March 29, 2021, to the Non-Exclusive Anticalin Platform License Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on May 17, 2021)

Subscription Agreement, dated March 29, 2021, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on May 17, 2021)

Clinical Trial Collaboration and Supply Agreement, dated August 10, 2020, by and between Pieris Pharmaceuticals, Inc. and Eli Lilly and Company (Filed With SEC on November 4, 2020)

Amendment No. 1 to the February 8, 2018 License and Collaboration Agreement by and among Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH and Seattle Genetics, Inc (Filed With SEC on August 10, 2020)

Amendment No. 1 to the February 8, 2018 Platform Agreement by and among Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH and Seattle Genetics, Inc (Filed With SEC on August 10, 2020)

Pieris Pharmaceuticals, Inc. 2020 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on June 29, 2020)

Exchange Agreement by and among Pieris Pharmaceuticals, Inc. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P.,... (Filed With SEC on April 6, 2020)

Description of Registered Securities (Filed With SEC on March 13, 2020)

Letter Amendment to the License and Collaboration Agreement by and between Les Laboratoires Servier, Institut de Recherches Internationales Servier, Pieris Pharmaceuticals, Inc.... (Filed With SEC on March 13, 2020)

Letter Agreement by and between the Registrant and Louis A. Matis, M.D., dated as of January 8, 2020 (Filed With SEC on March 13, 2020)

Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 13, 2020)

Amendment No. 1 to Lease Agreement by and between Pieris GmbH and Hallbergmoos Grundvermgen GmbH, dated May 21, 2019 (English translation) (Filed With SEC on March 13, 2020)

Amendment No. 2 to Lease Agreement by and between Pieris GmbH and Hallbergmoos Grundvermgen GmbH, dated February 13, 2020 (English translation) (Filed With SEC on March 13, 2020)

Managing Director Services Agreement by and between Pieris Pharmaceuticals GmbH and Hitto Kaufmann, PhD., dated February 20, 2019 (Filed With SEC on November 12, 2019)

Non-Qualified Stock Option Agreement by and between the Registrant and Hitto Kaufmann, Ph.D., dated as of August 30, 2019 (Filed With SEC on November 12, 2019)

Securities Purchase Agreement, dated November 2, 2019, by and among the Company and the Investors named therein (Filed With SEC on November 4, 2019)

Form of Warrant to purchase Common Stock (Filed With SEC on November 4, 2019)

Registration Rights Agreement, dated November 2, 2019, by and among the Company and the Investors named therein (Filed With SEC on November 4, 2019)

Open Market Sale Agreement, dated as of August 9, 2019, by and between Pieris Pharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on August 9, 2019)

Pieris Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 9, 2019)

Subtenant Recognition and Attornment Agreement, by and among Pieris Pharmaceuticals, Inc., 225 State Street, LLC, and Berenberg Capital Markets LLC, dated as of May 31, 2019 (Filed With SEC on August 9, 2019)

Pieris Pharmaceuticals, Inc. 2019 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on July 31, 2019)

Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 18, 2019)

Lease Agreement by and between Pieris GmbH and Hallbergmoos Grundvermgen GmbH, dated October 24, 2018 (Filed With SEC on March 18, 2019)

Exchange Agreement by and among Pieris Pharmaceuticals, Inc. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P.,... (Filed With SEC on February 4, 2019)

Pieris Pharmaceuticals, Inc. 2018 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on July 26, 2018)

Pieris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan (Filed With SEC on July 26, 2018)

Underwriting Agreement, dated February 14, 2018, by and among the Company, Jefferies LLC, Cowen and Company, LLC, and Evercore Group L.L.C (Filed With SEC on February 14, 2018)

Stock Option Agreement, dated August 9, 2017, between Pieris Pharmaceuticals Inc. and Allan Reine,.M.D (Filed With SEC on November 13, 2017)

CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on August 11, 2017)

CONFIDENTIAL TREATMENT REQUESTED AMENDMENT 1 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between (Filed With SEC on August 11, 2017)

CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on August 11, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on August 11, 2017)

CONFIDENTIAL TREATMENT REQUESTED EXCLUSIVE OPTION AGREEMENT (Filed With SEC on May 15, 2017)

PIERIS PHARMACEUTICALS, INC. Stock Option Grant Notice Stock Option Grant under the Companys 2016 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on March 30, 2017)

AMENDMENT NO. 1 TO DEFINITIVE LICENSE AND TRANSFER AGREEMENT (Filed With SEC on March 30, 2017)

LICENSE AND COLLABORATION AGREEMENT BETWEEN LESLABORATOIRES SERVIER INSTITUT DE RECHERCHES INTERNATIONALES SERVIER AND PIERISPHARMACEUTICALS, INC. PIERIS PHARMACEUTICALS GMBH... (Filed With SEC on March 30, 2017)

NON-EXCLUSIVE ANTICALIN® PLATFORM TECHNOLOGY LICENSE AGREEMENT (Filed With SEC on March 30, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on March 30, 2017)

CONSULTING AGREEMENT (Filed With SEC on March 30, 2017)

PIERIS PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on March 30, 2017)

PIERIS PHARMACEUTICALS, INC. COMMON STOCK SALES AGREEMENT (Filed With SEC on October 5, 2016)

CONFIDENTIAL TREATMENT REQUESTED DEFINITIVE LICENSE ANDTRANSFER AGREEMENT (Filed With SEC on August 11, 2016)

PIERIS PHARMACEUTICALS, INC. 2016 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN (Filed With SEC on July 1, 2016)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on June 6, 2016)

PIERIS PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK Original Issue Date: June , 2016 (Filed With SEC on June 6, 2016)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on June 6, 2016)

CONFIDENTIAL TREATMENT REQUESTED LICENSE AND TRANSFER AGREEMENT (Filed With SEC on May 12, 2016)

PIERIS PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on May 12, 2016)

CONFIDENTIAL TREATMENT REQUESTED Research Collaboration and License Agreement (Filed With SEC on March 23, 2016)

EMPLOYMENTAGREEMENT (Filed With SEC on November 13, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on November 13, 2015)

AGREEMENT OF SUBLEASE BERENBERG CAPITAL MARKETS LLC SUBLANDLORD AND PIERIS PHARMACEUTICALS INC. SUBTENANT (Filed With SEC on November 13, 2015)

Shares Pieris Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on June 24, 2015)

CONFIDENTIAL TREATMENT REQUESTED COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on March 30, 2015)

CONFIDENTIAL TREATMENT REQUESTED Collaboration Research and Technology Licensing Agreement (Filed With SEC on March 30, 2015)

CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on March 30, 2015)

CONFIDENTIAL TREATMENT REQUESTED RESEARCH AND LICENSING AGREEMENT between (Filed With SEC on March 30, 2015)

CONFIDENTIAL TREATMENT REQUESTED SIDE AGREEMENT to theCollaboration and License Agreement between Sanofi, Sanofi-Pasteur and Pieris (Filed With SEC on February 17, 2015)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on December 23, 2014)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on December 23, 2014)

COMMON STOCK PURCHASE WARRANT PIERIS PHARMACEUTICALS, INC. (Filed With SEC on December 23, 2014)

ACQUISITION AGREEMENT (Filed With SEC on December 18, 2014)

PIERIS PHARMACEUTICALS, INC. 2014 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN (Filed With SEC on December 18, 2014)

PIERIS PHARMACEUTICALS, INC. Stock Option Grant Notice Stock Option Grant under the Companys 2014 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on December 18, 2014)

CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on December 18, 2014)

CONFIDENTIAL TREATMENT REQUESTED COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on December 18, 2014)

CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on December 18, 2014)

CONFIDENTIAL TREATMENT REQUESTED Collaboration Research and Technology Licensing Agreement (Filed With SEC on December 18, 2014)

CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on December 18, 2014)

CONFIDENTIAL TREATMENT REQUESTED RESEARCH AND LICENSING AGREEMENT between (Filed With SEC on December 18, 2014)

INDEMNIFICATION AGREEMENT (Filed With SEC on December 18, 2014)

Management Agreement (the Agreement) between (Filed With SEC on December 18, 2014)

Amendment Agreement between (Filed With SEC on December 18, 2014)

AMENDED AND RESTATED MANAGEMENT AGREEMENT between (Filed With SEC on December 18, 2014)

Acknowledgement and Waiver Agreement between (Filed With SEC on December 18, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on December 18, 2014)

Management Agreement between (Filed With SEC on December 18, 2014)

CONSULTING AGREEMENT (the Agreement) (Filed With SEC on December 18, 2014)

Employment Agreement between (Filed With SEC on December 18, 2014)

Amendment to the Employment Agreement dated January 28, 2013 between (Filed With SEC on December 18, 2014)

Amendment to the Employment Agreement dated October 21, 2014 between (Filed With SEC on December 18, 2014)

Management Agreement (The Agreement) between (Filed With SEC on December 18, 2014)

CONSULTING AGREEMENT (Filed With SEC on December 18, 2014)

Rental account no. 130222 1st upper floor units 1.01 to1.08 (Filed With SEC on December 18, 2014)

Convertible Bridge Loan Agreement Dated November 12, 2012 between (Filed With SEC on December 18, 2014)

Amendment to the Convertible Bridge Loan Agreement dated November 12, 2012 between (Filed With SEC on December 18, 2014)

PARTICIPATION AGREEMENT Contract on the establishment of a silent partnership (Filed With SEC on December 18, 2014)

Ruth Oppenheimer, M.A. (Oxford) Offenlich bestelite Übersetzerin für die englische Sprache / Publicly appointed translator for German & English Am Graben le, 86925 Fuchstal,... (Filed With SEC on December 18, 2014)

Settlement Agreement between (Filed With SEC on December 18, 2014)

Convertible Bridge Loan Agreement Dated April 14, 2014 between (Filed With SEC on December 18, 2014)

Consolidated Shareholders Agreement 2014 Pieris AG, Freising, Germany dated October 10, 2014 by and among (Filed With SEC on December 18, 2014)

Investment Agreement Pieris AG, Freising, Germany dated October 10, 2014 by and among (Filed With SEC on December 18, 2014)

Agreement by and between (Filed With SEC on December 18, 2014)

SPLIT-OFF AGREEMENT (Filed With SEC on December 18, 2014)

GENERAL RELEASE AGREEMENT (Filed With SEC on December 18, 2014)

Category

Industry

Companies

Contracts

PIERIS PHARMACEUTICALS, INC. Contracts & Agreements